Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study

@article{Prete2009SorafenibPO,
  title={Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study},
  author={Salvatore Del Prete and Liliana Montella and Michele Caraglia and Luigi Maiorino and Gregorio Cennamo and Vincenzo Montesarchio and Guido Piai and Antonio Febbraro and Luciano Tarantino and Elena Capasso and Giovannella Palmieri and Rosario Guarrasi and Maddalena Bianco and Rosanna Mamone and Clementina Savastano and Agata Pisano and L D'Onofrio and Antonietta Sabia and Alberto D’Agostino and Vincenzo Faiola and Raffaele Addeo},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2009},
  volume={66},
  pages={837-844}
}
Advanced hepatocellular carcinoma (HCC) not eligible for local therapies has limited chances of cure. Sorafenib is a multikinase inhibitor with proven activity in advanced HCC. Octreotide is used in this setting with conflicting results. Treatment with sorafenib and long-acting octreotide was tested in advanced HCC to evaluate safety and activity. Fifty patients with advanced HCC, Child-Pugh A or B, received sorafenib at a dosage of 800 mg/day for 28 days with a following week of rest and long… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
37 Extracted Citations
35 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 37 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 35 references

presence of lung metastasis predicts poor response

  • T Yau, P Chan, population Ng KK et al Phase 2 open-label study of single-age Asian
  • Cancer 115:428–436 844 Cancer Chemother…
  • 2010
1 Excerpt

Similar Papers

Loading similar papers…